Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer

This study is testing a combination of two cancer drugs — bortezomib and cisplatin — in women with recurrent or metastatic breast cancer that has not responded to standard treatments. **You may be eligible if...** - You are a woman aged 18 or older with confirmed advanced or metastatic breast cancer - You have tumor tissue available for testing - Standard treatments have failed in your case - You have at least one measurable tumor on imaging - You are in reasonably good overall health (ECOG score of 0-2) - Your expected survival is at least 12 weeks - Your blood counts and organ function meet the required levels **You may NOT be eligible if...** - You have active brain metastases - You have severe heart, liver, or kidney problems - You are pregnant or breastfeeding - You have an active serious infection Talk to your doctor to see if this trial is right for you.